Quick Answer
LENZ Therapeutics, Inc. reported Operating Income of -$91.14 million for fiscal year 2025.
LENZ Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$91.14M | -55.5% |
| 2024 | -$58.61M | +19.1% |
| 2023 | -$72.43M | +31.4% |
| 2022 | -$105.64M | -74.8% |
| 2021 | -$60.44M | -347.7% |
| 2020 | -$13.50M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$18.89M | -45.9% | -12.0% |
| June 30, 2025 | -$16.86M | -17.5% | +0.4% |
| March 31, 2025 | -$16.93M | -5.2% | -30.8% |
| September 30, 2024 | -$12.95M | +34.8% | +9.8% |
| June 30, 2024 | -$14.35M | +4.1% | +10.8% |
| March 31, 2024 | -$16.09M | -27.5% | +19.0% |
| September 30, 2023 | -$19.86M | +24.0% | -32.8% |
| June 30, 2023 | -$14.96M | +44.1% | -18.6% |
- LENZ Therapeutics, Inc. showed a decrease of -55.5% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, LENZ Therapeutics, Inc.’s operating income has declined by 575.1% (from -$13.50 million to -$91.14 million).
- The most recent figure is from LENZ Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: